# Stereotaxis, Inc. (STXS)

> Source: Nexqual · https://nexqual.com/STXS · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Stereotaxis, Inc. (STXS), nexqual.com/STXS" · informational, not investment advice.

**Price:** USD 1.05 (+0.00% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 1.05 · day 1.02–1.06 · 52w 1.02–3.15 · market cap $105M · ASE

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $30.1M, net income -$22.3M (-74.2% margin), free cash flow -$15.5M (SEC filings).
- Analysts: Buy (mean 1.67 on a 1–5 scale) (3 analysts), mean target USD 3 (range 3–3).
- Total return with dividends: 1Y -65.3% vs S&P 500 +18.1%; 5Y -82.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-16, EPS estimate USD -0.06, revenue estimate $9.6M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $35.0M | $28.1M | $26.8M | $26.9M | $32.4M | $30.1M |
| Gross profit | $23.2M | $18.5M | $14.9M | $14.6M | $17.1M | — |
| Operating income | -$12.9M | -$18.8M | -$21.8M | -$24.7M | -$22.1M | -$22.8M |
| Net income | -$10.7M | -$18.3M | -$20.7M | -$24.0M | -$21.6M | -$22.3M |
| EPS (diluted) | -$0.16 | -$0.26 | -$0.27 | -$0.30 | -$0.25 | — |
| Free cash flow | -$4.3M | -$10.8M | -$9.5M | -$8.5M | -$13.8M | -$15.5M |
| Gross margin | 66.3% | 65.6% | 55.5% | 54.2% | 52.7% | — |
| Operating margin | -36.8% | -66.7% | -81.6% | -91.9% | -68.3% | -75.7% |
| Net margin | -30.6% | -65.0% | -77.4% | -89.3% | -66.8% | -74.2% |
| Revenue growth | +31.5% | -19.6% | -4.9% | +0.5% | +20.3% | — |
| Cash + short-term investments | $38.7M | $28.4M | — | $12.2M | $13.4M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 3.5x · P/B 8.6x · FCF yield -14.73% · Earnings yield -21.22% · Dividend yield (paid, TTM) 0.00%

## Analysts
Consensus Buy (mean 1.67 on a 1–5 scale), 3 analysts; mean target USD 3 (low 3, high 3).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-27 | Citizens | Target lowered | Market Outperform | $4 → $3 |
| 2026-08-12 | TD Cowen | Target lowered | Buy | $5 → $3 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -65.3% | -82.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -65.5% | -29.2% |
| Volatility (annualized) | 51.3% | 59.0% |
| Max drawdown | -66.1% (Oct 2025→Oct 2026) | -83.9% (Nov 2021→Oct 2026) |

## Peers (Medical Instruments & Supplies)
KMTS (Kestra Medical Technologies, Lt) USD 28.68 +6.34% · XRAY (DENTSPLY SIRONA Inc.) USD 8.83 +3.76% · LMAT (LeMaitre Vascular, Inc.) USD 83.16 +1.97% · ATRC (AtriCure, Inc.) USD 57.78 +1.60% · WRBY (Warby Parker Inc.) USD 24.59 -7.28% · PLSE (Pulse Biosciences, Inc) USD 45.59 -6.08%

## More
Full page: https://nexqual.com/STXS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt